[go: up one dir, main page]

DK1856042T3 - Substituerede gamma-lactamer som terapeutiske midler - Google Patents

Substituerede gamma-lactamer som terapeutiske midler

Info

Publication number
DK1856042T3
DK1856042T3 DK06737027.0T DK06737027T DK1856042T3 DK 1856042 T3 DK1856042 T3 DK 1856042T3 DK 06737027 T DK06737027 T DK 06737027T DK 1856042 T3 DK1856042 T3 DK 1856042T3
Authority
DK
Denmark
Prior art keywords
lactams
therapeutic agents
substituted gamma
gamma
substituted
Prior art date
Application number
DK06737027.0T
Other languages
English (en)
Inventor
David W Old
Danny T Dinh
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of DK1856042T3 publication Critical patent/DK1856042T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/267—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/402—1-aryl substituted, e.g. piretanide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
DK06737027.0T 2005-03-10 2006-03-06 Substituerede gamma-lactamer som terapeutiske midler DK1856042T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66074805P 2005-03-10 2005-03-10
PCT/US2006/007797 WO2006098918A2 (en) 2005-03-10 2006-03-06 Substituted gamma lactams as therapeutic agents

Publications (1)

Publication Number Publication Date
DK1856042T3 true DK1856042T3 (da) 2012-09-17

Family

ID=36579663

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06737027.0T DK1856042T3 (da) 2005-03-10 2006-03-06 Substituerede gamma-lactamer som terapeutiske midler

Country Status (21)

Country Link
US (4) US7476747B2 (da)
EP (1) EP1856042B1 (da)
JP (2) JP5197354B2 (da)
KR (1) KR101276449B1 (da)
CN (2) CN105520941B (da)
AR (1) AR053162A1 (da)
AU (1) AU2006223514A1 (da)
BR (1) BRPI0609021A2 (da)
CA (1) CA2599425C (da)
DK (1) DK1856042T3 (da)
ES (1) ES2388929T3 (da)
HK (2) HK1116168A1 (da)
IL (1) IL185363A (da)
MX (1) MX2007010818A (da)
NO (1) NO341339B1 (da)
NZ (1) NZ560691A (da)
PL (2) PL1856042T3 (da)
RU (1) RU2412933C2 (da)
TW (1) TWI386391B (da)
WO (1) WO2006098918A2 (da)
ZA (1) ZA200706852B (da)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8673341B2 (en) 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US7091231B2 (en) * 2004-12-10 2006-08-15 Allergan, Inc. 12-Aryl prostaglandin analogs
MX2007010818A (es) * 2005-03-10 2007-11-12 Allergan Inc Gamma lactamas sustituidas como agentes terapeuticos.
US7592364B2 (en) * 2006-02-28 2009-09-22 Allergan, Inc. Substituted gamma lactams as therapeutic agents
AU2007226957B2 (en) 2006-03-20 2013-08-15 Allergan, Inc. Substituted gamma lactams as prostaglandin EP2 agonists
US7553860B2 (en) * 2006-06-14 2009-06-30 Allergan, Inc. Substituted gamma lactams as therapeutic agents
NZ597866A (en) * 2006-08-11 2013-08-30 Allergan Inc Therapeutic lactams
EP2054409A2 (en) * 2006-08-23 2009-05-06 Allergan, Inc. Therapeutic substituted thiazolidinones, oxazolidinones, and related compounds
US8377984B2 (en) * 2008-01-29 2013-02-19 Allergan, Inc. Substituted gamma lactams as therapeutic agents
JP5566692B2 (ja) 2007-01-31 2014-08-06 アラーガン インコーポレイテッド 治療薬としての置換ガンマラクタム類
CA2678191A1 (en) 2007-02-15 2008-08-21 Allergan, Inc. Gamma-lactams for the treatment of glaucoma or elevated intraocular pressure
US7589213B2 (en) 2007-04-27 2009-09-15 Old David W Therapeutic substituted lactams
ES2395875T3 (es) 2007-05-23 2013-02-15 Allergan, Inc. Lactamas cíclicas para el tratamiento del glaucoma o de la presión intraocular elevada
US7781465B2 (en) * 2007-08-21 2010-08-24 Allergan, Inc. Therapeutic oxazolidinones and thiazolidinones
US20090062361A1 (en) * 2007-08-30 2009-03-05 Allergan, Inc. Therapeutic hydantoins
US8440819B2 (en) * 2008-02-22 2013-05-14 Allergan, Inc. Therapeutic substituted beta-lactams
US7956055B2 (en) * 2008-03-25 2011-06-07 Allergan, Inc. Substituted gamma lactams as therapeutic agents
US20110152328A1 (en) * 2008-04-16 2011-06-23 Whitcup Scott M Combination Therapy For Glaucoma
BRPI0911406A2 (pt) * 2008-04-24 2015-10-06 Allergan Inc gama lactames substituídos como agentes terapêuticos
BRPI0911347A2 (pt) 2008-04-24 2018-03-20 Allergan Inc gama lactamas substituídas como agentes terapêuticos
JP2011519937A (ja) * 2008-05-09 2011-07-14 アラーガン インコーポレイテッド 治療用ｎ‐アリールまたはｎ‐ヘテロアリールピラゾリジンおよびピラゾリジノン誘導体
US7985765B2 (en) 2008-08-20 2011-07-26 Allergan, Inc. Therapeutic substituted pyrroles
US20100247606A1 (en) * 2009-03-25 2010-09-30 Allergan, Inc. Intraocular sustained release drug delivery systems and methods for treating ocular conditions
US8952051B2 (en) * 2009-11-05 2015-02-10 Allergan, Inc. Ophthalmic formulations containing substituted gamma lactams and methods for use thereof
US20110136872A1 (en) * 2009-12-09 2011-06-09 Burk Robert M Stable aqueous compositions of prostglandin agonist prodrugs and methods for use thereof
CA2808407A1 (en) * 2010-08-17 2012-02-23 Allergan, Inc. Ep2 or ep4 agonists for treating corneal haze
US8741281B2 (en) * 2010-08-19 2014-06-03 Allergan, Inc. Compositions and soft tissue replacement methods
EP2605762A1 (en) * 2010-08-19 2013-06-26 Allergan, Inc. Compositions comprising adipose tissue and a pge2 analogue and their use in the treatment of a soft tissue condition
US8697057B2 (en) * 2010-08-19 2014-04-15 Allergan, Inc. Compositions and soft tissue replacement methods
AU2012223256A1 (en) * 2011-03-03 2013-09-19 Allergan, Inc. Silicone-based ophthalmic formulations
US20130345149A1 (en) * 2011-03-03 2013-12-26 Allergan, Inc. Silicone-based ophthalmic formulations
CA2882138C (en) * 2012-08-21 2020-10-27 Allergan, Inc. Process for the synthesis of substituted gamma lactams
WO2014078446A2 (en) * 2012-11-16 2014-05-22 Allergan, Inc. Skin wound healing and scar reduction with prostaglandin ep4 agonist combinations
EP3062775B1 (en) 2013-10-31 2017-12-06 Allergan, Inc. Prostamide-containing intraocular implants and methods of use thereof
CA2962766A1 (en) * 2014-10-02 2016-04-07 Allergan, Inc. Ester prodrugs of gamma-lactams and their use
RU2568603C1 (ru) * 2015-01-15 2015-11-20 Федеральное агентство научных организаций (ФАНО России) Федеральное государственное бюджетное учреждение науки Институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) Производные простагландина, обладающие противовоспалительной и анальгезирующей активностью

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5462968A (en) * 1994-01-19 1995-10-31 Allergan, Inc. EP2 -receptor agonists as agents for lowering intraocular pressure
US6437146B1 (en) 1998-09-25 2002-08-20 Fujisawa Pharmaceutical Co., Ltd. Oxazole compounds as prostaglandin e2 agonists or antagonists
BR0211201A (pt) * 2001-07-16 2004-07-13 Hoffmann La Roche Composto, processo para a preparação desse composto, sua utilização, composição farmacêutica que compreende o mesmo e método para o tratamento de uma enfermidade em um mamìfero
EP1442033B1 (en) 2001-11-05 2005-09-28 Allergan, Inc. Omega-cycloalkyl 17-heteroaryl prostaglandin e2 analogs as ep2-receptor agonists
US7402605B2 (en) * 2002-03-05 2008-07-22 Ono Pharmaceutical Co., Ltd. 8-azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient
US6573294B1 (en) * 2002-05-14 2003-06-03 Allergan, Inc. 8-azaprostaglandin analogs as agents for lowering intraocular pressure
US7419999B2 (en) * 2002-06-10 2008-09-02 Applied Research Systems Ars Holding N.V. Gamma lactams as prostaglandin agonists and use thereof
AU2003275838A1 (en) * 2002-10-25 2004-05-13 Beunard, Jean-Luc Pyrrolidin-2-on derivatives as ep4 receptor agonists
MX2007010818A (es) * 2005-03-10 2007-11-12 Allergan Inc Gamma lactamas sustituidas como agentes terapeuticos.
US7592364B2 (en) * 2006-02-28 2009-09-22 Allergan, Inc. Substituted gamma lactams as therapeutic agents

Also Published As

Publication number Publication date
JP5762379B2 (ja) 2015-08-12
IL185363A0 (en) 2008-02-09
US7473702B2 (en) 2009-01-06
TW200714583A (en) 2007-04-16
CN105520941A (zh) 2016-04-27
KR20070110920A (ko) 2007-11-20
AU2006223514A1 (en) 2006-09-21
CA2599425A1 (en) 2006-09-21
US20070287742A1 (en) 2007-12-13
RU2412933C2 (ru) 2011-02-27
AR053162A1 (es) 2007-04-25
NZ560691A (en) 2011-03-31
WO2006098918B1 (en) 2006-12-28
PL1856042T3 (pl) 2012-11-30
US20090233980A1 (en) 2009-09-17
WO2006098918A3 (en) 2006-11-23
CN101137622A (zh) 2008-03-05
US7973071B2 (en) 2011-07-05
CN105520941B (zh) 2020-05-01
TWI386391B (zh) 2013-02-21
IL185363A (en) 2012-03-29
US20110275692A1 (en) 2011-11-10
WO2006098918A2 (en) 2006-09-21
JP2008533011A (ja) 2008-08-21
NO341339B1 (no) 2017-10-16
JP2013032374A (ja) 2013-02-14
EP1856042B1 (en) 2012-06-27
KR101276449B1 (ko) 2013-06-20
BRPI0609021A2 (pt) 2010-01-12
JP5197354B2 (ja) 2013-05-15
US7476747B2 (en) 2009-01-13
PL384090A1 (pl) 2008-06-23
US20070265330A1 (en) 2007-11-15
HK1116168A1 (en) 2008-12-19
HK1223851A1 (zh) 2017-08-11
ZA200706852B (en) 2008-09-25
EP1856042A2 (en) 2007-11-21
CA2599425C (en) 2013-04-30
MX2007010818A (es) 2007-11-12
NO20074295L (no) 2007-12-07
ES2388929T3 (es) 2012-10-19
RU2007133581A (ru) 2009-04-20

Similar Documents

Publication Publication Date Title
DK1856042T3 (da) Substituerede gamma-lactamer som terapeutiske midler
NL301109I2 (nl) Cabotegravir
CY2014030I1 (el) Θεραπευτικες συνθεσεις που περιλαμβανουν ingenol-3-angelate
ATE525088T1 (de) Kombinationstherapie
DK3424932T3 (da) Bronophthalider til terapeutisk anvendelse
EP1962961A4 (en) HALF-BODY: THERAPEUTIC AGENTS ACTIVATED BY DIMÉRIZATION
DK1888595T3 (da) Spiro-oxindolforbindelser og deres anvendelser som terapeutiske midler
CY2013047I2 (el) Ενωσεις διαρυλυδαντοϊνης
DE602006017807D1 (de) Oberflächeninjizierungsvorrichtung
DK1902037T3 (da) 2,4-diamino-pyrimidiner som auroainhibitorer
DE602006002078D1 (de) Gurtbandaufwickelvorrichtung
EP1893244A4 (en) AGENTS FOR IMAGING
DE602006020033D1 (de) Nadeleinführinstrument
DE602006000345D1 (de) Scheibenbremsaktuator
DK3190106T3 (da) Desferrithiocinpolyether-analoger
DE502006008475D1 (de) Wasserpumpenflügelrad
DE602006011096D1 (de) Flanschverbindungsvorrichtung
EP1916896A4 (en) NOT STEROID-antiandrogens
DE602006018502D1 (de) Ng
EP1905864A4 (en) TARGET CONTAINING OXIDE In Sm FOR USE IN VACUUM SPRAY
DE602006007774D1 (de) Zahnreinigungsmittel
DK2041128T3 (da) Substituerede gamma-lactamer som terapeutiske agenser
EP2111484A4 (en) POLYAMINE BRILLIANCE AGENT
BRPI0620820A2 (pt) dentifrício
BRPI0620807A2 (pt) dentifrício